PCR-based Approach for Determining the Genetic Risk Factors of Antipsychotic-Induced Metabolic Disorders
https://doi.org/10.52667/2712-9179-2022-2-1-67-72
Abstract
The antipsychotic-induced metabolic disorders (AIMD) are common side effects during the treatment of schizophrenia. Single nucleotide polymorphisms in the genes associated with AIMD, in particular in the leptin and neuropeptide Y genes were explored. The aim of this study was to develop a real-time PCR technique for SNP allele discrimination and allele frequency estimation in the Russian population. A total of 9 real-time PCR tests for rs7799039, rs1137101, rs8179183, rs16147, rs6837793, rs11100494, rs1414334, rs3813929 and rs518147 SNPs were developed and examined using 106 DNA samples. The revealed allele frequencies did not show any statistically significant differences with ones for the Caucasian population from Ensembl data base. Thus, our results are in accordance with the allele frequencies for the studied populations and allow using published data on the risk alleles for the development of new diagnostics PCR kits for the complex diagnostics of AIMD.
Keywords
antipsychotic,
leptin,
neuropeptide Y,
single nucleotide polymorphism,
pharmacogenetics,
pyrosequencing,
real-time PCR
Supporting agencies: This research received no external funding
About the Authors
K. O. Mironov
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
Konstantin O. Mironov
Moscow, 111123; Tel.: 8-495-788-00-02
I. I. Gaponova
Russian Federation
Irina I. Gaponova
Moscow, 111123
V. I. Korchagin
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
Vitaly I. Korchagin
Moscow, 111123
A. S. Esman
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
Anna S. Esman
Moscow, 111123
E. A. Dunaeva
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
Elena A. Dunaeva
Moscow, 111123
V. A. Zhivotova
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
Vera A. Zhivotova
Moscow, 111123
V. S. Dobrodeeva
Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
Vera S. Dobrodeeva
Saint-Petersburg, 192019
N. A. Shnayder
Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; Shared Core Facilities Molecular and Cell Technologies, V. F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Natalia A. Shnayder
Saint-Petersburg, 192019; Krasnoyarsk, 660022
N. G. Neznanov
Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
Nikolay G. Neznanov
Saint-Petersburg, 192019
R. F. Nasyrova
Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
Regina F. Nasyrova
Saint-Petersburg, 192019
References
1. Axelrod, E.V.; Mironov, K.O.; Dunaeva, E.A.; Shipulin, G.A. The comparison of three molecular genetic techniques for identifying major mutations in gene HFE related to development of inherent hemochromatosis. Clinical Laboratory Diagnosis, 2016, 61, 5, 316-320 (In Russ.), doi: 10.18821/0869-2084-2016-61-5-316-320.
2. Baranov, V.S. Genenic passport – the basic of individual predictive medicine. SPb.: N-L, 2009, 528 (In Russ.), ISBN 978-5-94869-084-1.
3. Dobrodeeva, V.S.; Shnayder, N.A.; Mironov, K.O.; Nasyrova, R.F. Pharmacogenetic markers of antipsychotic-induced weight gain: leptin and neuroepeptide Y. V.M. Behterev Rewiev of Psychiatry and Medical Psychology, 2021, 1, 3-10 (In Russ.), doi:10.31363/2313-7053-2021-1-3-10.
4. Nasyrova, R.F.; Neznanov, N.G. Clinical psychopharmacogenetics. SPb.: DEAN, 2019, 405 (InRuss.), ISBN 978-5-6043573-7-8.
5. Mironov, K.O.; Dunaeva, E.A.; Dribnokhodova, O.P.; Shipulin, G.A. Experience in using genetic analysis systems based on pyrosequencing technology. Spravocnik zaveduusego KDL, 2016, 5, 33–42 (In Russ.).
6. Mironov, K.O.; Titkov, A.V.; Kuleshov, K.V.; Kolyasnikova, N.M.; Bondarenko, E.I.; Platonov, A.E. Development and application of the technique for identification of Borrelia miyamotoi surface antigens. Journal of Microbiology, Epidemiology and Immunobiology, 2021, 98, 3,339-350 (In Russ.), doi:10.36233/0372-9311-142.
7. Nasyrova, R.F.; Ivanov, M.V.; Neznanov, N.G. Introduction to psychopharmacogenetics. SPb.: Izdatel'skii tsentr SPb NIPNI im. V. M. Bekhtereva, 2015, 272 (In Russ.), ISBN 978-5-7452-0020-5.
8. Nasyrova, R.F.; Sivakova, N.A.; Ivashchenko, D.V.; Sosin, D.N.; Ershov, E.E.; Sosina, K.A.; Akhmetova, L.S.; Volikova, O.V.; Beybalayeva, T.Z.; Neznanov, N.G. Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art. V.M. Bekhterev Review of Psychiatry and Medical Psychology, 2016, 3, 67-80 (In Russ.).
9. Flicek, P.; Aken, B.L.; Ballester, B.; Beal. K.; Bragin, E.; Brent, S. et al. Ensembl's 10th year. Nucleic Acids Res, 2010, 38, 557–562, doi: 10.1093/nar/gkp972.
10. Myers, T.A.; Chanock, S.J.; Machiela, M.J. LDlinkR: An R package for rapidly calculating linkage disequilibrium statistics in diverse populations. Front Genet., 2020, 28, 11, 157, doi: 10.3389/fgene.2020.00157.
11. Neznanov, N.G. A paradigm shift to treat psychoneurological disorders. Personalized Psychiatry and Neurology 2021, 1 (1): 1-2.
12. Dobrodeeva, V. S.; Abdyrahmanova, A. K.; Nasyrova, R. F. Personalized approach to antipsychotic-induced weight gain prognosis. Personalized Psychiatry and Neurology 2021, 1 (1): 3-10. doi: 10.52667/2712-9179-2021-1-1-3-10
13. Dobrodeeva, V.S.; Shnayder, N.A.; Novitsky, M.A.; Asadullin, A.R.; Vaiman, E.E.; Petrova, M.M.; Limankin, O.V.; Neznanov, N.G.; Garganeeva, N.P.; Nasyrova, R.F. Association of a single-nucleotide variant rs11100494 of the NPY5R gene with antipsychotic-induced metabolic disorders. Pharmaceutics 2022, 14, 222. doi: 10.3390/pharmaceutics14020222
Review
For citations:
Mironov K.O., Gaponova I.I., Korchagin V.I., Esman A.S., Dunaeva E.A., Zhivotova V.A., Dobrodeeva V.S., Shnayder N.A., Neznanov N.G., Nasyrova R.F. PCR-based Approach for Determining the Genetic Risk Factors of Antipsychotic-Induced Metabolic Disorders. Personalized Psychiatry and Neurology. 2022;2(1):67-72. https://doi.org/10.52667/2712-9179-2022-2-1-67-72
Views:
520
Email this article 